News & Media
Learn more about the latest happenings at Otsuka. Select to see US news or read our press releases. You can also stay up to date with our global news in the link below.
Media Contact:
Senior Director, External Communications,
Otsuka America Pharmaceutical, Inc
Princeton, New Jersey – April 18, 2016 – Otsuka America Pharmaceutical, Inc. and Otsuka Pharmaceutical Development & Commercialization (Otsuka) commend the recent announcement from President Obama that he will establish an inter-agency Mental Health and Substance Use Disorder Parity Task Force to better ensure compliance with and implementation of requirements related to mental health
The safety and efficacy of REXULTI (brexpiprazole) as maintenance treatment in adults with schizophrenia aged 18 to 65 years was demonstrated in a 52-week randomized withdrawal trial.The anticipated date for the FDA to complete its review of the proposed expanded labeling is September 23, 2016. REXULTI was approved by the U.S. FDA in July 2015 as a treatment for adults with schizophrenia and as
The first Digital Medicine, a drug/device product, combines Otsuka's ABILIFY® (aripiprazole) for serious mental illness, embedded with the Proteus® ingestible sensor in a single tablet to digitally record ingestion and, with patient consent, share information with their healthcare professionals and caregiversOtsuka and Proteus are pursuing a regulatory filing for a drug-device combination
Seven-year study matches the longest duration of follow-up for any CML treatment, including imatinib, based on approved prescribing information (PRINCETON, NJ, August 13, 2015) – Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka America Pharmaceutical, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an update to the Sprycel® (dasatinib) product labeling.